Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Abbott Laboratories (GB:0Q15)
LSE:0Q15
Holding GB:0Q15?
Track your performance easily
0Q15 Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$91.72 - $121.60
Previous Close$119.68
Volume4.77K
Average Volume (3M)23.79K
Market Cap
$205.12B
Enterprise Value$212.89B
Total Cash (Recent Filing)$7.22B
Total Debt (Recent Filing)$14.75B
Price to Earnings (P/E)35.6
Beta0.46
Next Earnings
Jan 22, 2025EPS Estimate
$1.34Last Dividend Ex-Date
Oct 15, 2024Dividend Yield1.83%
Share Statistics
EPS (TTM)3.29
Shares Outstanding1,739,897,004
10 Day Avg. Volume70
30 Day Avg. Volume23,785
Standard Deviation0.04
R-Squared0.01
Alpha0.03
Financial Highlights & Ratios
Price to Book (P/B)2.52
Price to Sales (P/S)5.04
Price to Cash Flow (P/CF)26.20
P/FCF Ratio33.30
Enterprise Value/Market CapN/A
Enterprise Value/Revenue5.23
Enterprise Value/Gross Profit9.62
Enterprise Value/Ebitda20.55
Forecast
1Y Price Target
$132.29Price Target Upside10.54% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering20
Abbott Laboratories News
Bulls Say, Bears Say
Bulls Say
Financial PerformanceRevenue and EPS beat the Street's forecasts, with organic sales growth for the base business at 8.2% and Med Devices showing 13.3% growth.
Market PositionBroad strength across medtech, including pipeline products such as TAVR in Structural Heart, supports ABT's strong market position.
Stock BuybackAbbott Laboratories has a new $7B share repurchase authorization which may help push adjusted EPS higher.
Bears Say
Earnings OutlookThe current consensus estimates for 2025 look 'very aggressive', raising concerns about the company's ability to meet these expectations.
Financial PerformanceThe company fell short of the Street sales target for Nutrition, and international core lab performance was impacted by VBP, particularly in China.
Litigation RisksA jury in St. Louis ordered ABT to pay $495M in the company's first necrotizing-enterocolitis case, with the amount much more than Reckitt due to St Louis jurisdiction allowing for punitive damages.
---
Options Prices
Currently, No data available
---
Ownership Overview
0.47% Insiders
24.53% Mutual Funds
1.08% Other Institutional Investors
55.06% Public Companies and
Individual Investors
0Q15 FAQ
What was Abbott Laboratories’s price range in the past 12 months?
Abbott Laboratories lowest share price was $91.72 and its highest was $121.60 in the past 12 months.
What is Abbott Laboratories’s market cap?
Currently, no data Available
When is Abbott Laboratories’s upcoming earnings report date?
Abbott Laboratories’s upcoming earnings report date is Jan 22, 2025 which is in 95 days.
How were Abbott Laboratories’s earnings last quarter?
Abbott Laboratories released its earnings results on Oct 16, 2024. The company reported $1.21 earnings per share for the quarter, beating the consensus estimate of $1.202 by $0.008.
Is Abbott Laboratories overvalued?
According to Wall Street analysts Abbott Laboratories’s price is currently Undervalued.
Does Abbott Laboratories pay dividends?
Abbott Laboratories pays a Quarterly dividend of $0.55 which represents an annual dividend yield of 1.83%. See more information on Abbott Laboratories dividends here
What is Abbott Laboratories’s EPS estimate?
Abbott Laboratories’s EPS estimate is $1.34.
How many shares outstanding does Abbott Laboratories have?
Abbott Laboratories has 1,739,897,000 shares outstanding.
What happened to Abbott Laboratories’s price movement after its last earnings report?
Abbott Laboratories reported an EPS of $1.21 in its last earnings report, beating expectations of $1.202. Following the earnings report the stock price went up 1.672%.
Which hedge fund is a major shareholder of Abbott Laboratories?
Among the largest hedge funds holding Abbott Laboratories’s share is Fisher Asset Management LLC. It holds Abbott Laboratories’s shares valued at 1B.
---
Abbott Laboratories Stock Smart Score
Company Description
Abbott Laboratories
Abbott Laboratories offers a diversified line of healthcare products. It operates through four reportable segments: Established Pharmaceutical Products International (includes international sales of branded generic pharmaceutical products), Nutritional Products Diagnostic Products and Medical Devices. The company was founded by Wallace Calvin Abbott in 1888 and is headquartered in Abbott Park, IL.
---
0Q15 Company Deck
---
0Q15 Earnings Call
Q3 2024
0:00 / 0:00
---
0Q15 Net sales Breakdown
42.10% Medical Devices
24.90% Diagnostic Products
20.33% Nutritional Products
12.63% Established Pharmaceutical Products
0.03% Other
---
0Q15 Stock 12 Month Forecast
Average Price Target
$132.29
▲(10.54% Upside)
Technical Analysis
Abbott Laboratories
―
Johnson & Johnson
―
Medtronic
―
Baxter International
―
Stryker
―
Best Analysts Covering 0Q15
1 Year
1 Year Success Rate
41/47 ratings generated profit
1 Year Average Return
+19.62%
reiterated a buy rating 6 days ago
Copying Jayson Bedford's trades and holding each position for 1 Year would result in 87.23% of your transactions generating a profit, with an average return of +19.62% per trade.
---